Long‐term treatment with the beta‐3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice
- 29 October 2016
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 36 (6) , 1511-1518
Abstract
Aims: To evaluate the effects of the beta‐3 adrenoceptor agonist, mirabegron in a mouse model of detrusor overactivity induced by obesity.Methods: C57BL/6 male mice were fed with standard chow or high‐fat diet for 12 weeks. Lean and obese mice were treated orally with mirabegron (10 mg/kg/day) from the last 2 weeks of diet. Cystometric evaluations, functional assays, protein expression for phosphodiesterase type 4 (PDE4), and cyclic adenosine monophosphate (cAMP) measurement were carried out.Results: In obese mice the body weight, epididymal fat mass, fasting glucose, and low‐density lipoprotein (LDL) levels were higher (P < 0.001) than in the lean mice. A reduction of 34% and 54% and an increase of 35% in the epididimal fat, LDL, and HDL levels (P < 0.05), respectively, were observed in the obese group treated with mirabegron, whereas no changes were seen in the lipid profile from lean mice. Obese group showed irregular micturition pattern, characterized by significant increases in frequency and non‐void contractions. Carbachol, potassium chloride, and electrical‐field stimulation induced detrusor smooth muscle (DSM) contractions, which were greater in bladders from obese mice than from lean mice. Two‐week treatment with mirabegron restored all the contractile response alterations in the DSM. Basal intracellular levels of cAMP were reduced (68%), whereas PDE4 protein expression was increased (54%) in bladder from obese mice. Mirabegron restored the cAMP levels in obese bladder, without changing the PDE4 expression.Conclusion: Mirabegron was able to completely restore the urinary alterations seen in the bladder from obese mice.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/13907-4)
This publication has 25 references indexed in Scilit:
- Prostaglandin E2 excitatory effects on rat urinary bladder: a comparison between the β-adrenoceptor modulation of non-voiding activity in vivo and micro-contractile activity in vitroNaunyn-Schmiedeberg's Archives of Pharmacology, 2015
- The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: New therapeutic indication?The Prostate, 2014
- Prevalence of Childhood and Adult Obesity in the United States, 2011-2012JAMA, 2014
- Protective Effect of a β3-Adrenoceptor Agonist on Bladder Function in a Rat Model of Chronic Bladder IschemiaEuropean Urology, 2013
- Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeysNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Modulation of non‐voiding activity by the muscarinergic antagonist tolterodine and the β 3 ‐adrenoceptor agonist mirabegron in conscious rats with partial outflow obstructionBJU International, 2012
- The Impact of Obesity on Urinary Incontinence Symptoms, Severity, Urodynamic Characteristics and Quality of LifeJournal of Urology, 2010
- Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder FunctionThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Trends and Correlates of Class 3 Obesity in the United States From 1990 Through 2000JAMA, 2002
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002